Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020
The update will be provided via a press release after market close, and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis.
Neera Ravindran, M.D. VP, Head of Investor Relations & Strategic Communicationsnravindran@vir.bio +1-415-506-5256 Media Julie Normart W2O Groupjnormart@w2ogroup.com +1-559-974-3245
Source: Vir Biotechnology, Inc.